ABA Section of Antitrust Law
Health Care & Pharmaceuticals Committee
Presents

Biosimilars: Policy Developments and Emerging Competition Issues

January 12, 2015
12:00 - 1:30 p.m. EST

This program will address recent developments relating to the unique challenges that follow-on biologics (also known as biosimilars) present for regulators, policymakers, and drugmakers. While biosimilars are not yet available in the U.S. market, sales have begun in Europe. Among other things, this panel will discuss Europe’s experience with biosimilars and implications that the European experience has for U.S. regulation and sales of biosimilars, expected to begin in 2015.

Click “REGISTER NOW” button to register.

Antitrust Members: FREE
Antitrust Section members may attend unlimited programs at no additional cost.

Non-Members: $25
Learn about Section membership, or call 800-285-2221 to join with source code RAT14IP25.

Instructions for accessing the live program will be provided in a confirmation email. For this and all upcoming events visit http://AmBar.org/ATEvents.
You can attend by phone or in person at Cornerstone Research, 1919 Pennsylvania Avenue NW, #600, Washington, DC 20006

Moderator
• Amanda G. Lewis, Federal Trade Commission

Panelists
• Maria Salgado, Cornerstone Research
• Darren Tucker, Morgan, Lewis & Bockius LLP
• Alexander Roediger, MSD (Europe) Inc.
• Susan DeSanti, Federal Trade Commission

CLE
The ABA is not seeking CLE credit for this program.

Audio Archive
Provided all releases are obtained, MP3 recordings of this program will be available to Section members on the Committee Program Audio page.